Literature DB >> 20061561

Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia.

Nagaja Capitani1, Orso Maria Lucherini, Elisa Sozzi, Micol Ferro, Nico Giommoni, Francesca Finetti, Giulia De Falco, Emanuele Cencini, Donatella Raspadori, Pier Giuseppe Pelicci, Francesco Lauria, Francesco Forconi, Cosima T Baldari.   

Abstract

Intrinsic apoptosis defects underlie to a large extent the extended survival of malignant B cells in chronic lymphocytic leukemia (CLL). Here, we show that the Shc family adapter p66Shc uncouples the B-cell receptor (BCR) from the Erk- and Akt-dependent survival pathways, thereby enhancing B-cell apoptosis. p66Shc expression was found to be profoundly impaired in CLL B cells compared with normal peripheral B cells. Moreover, significant differences in p66Shc expression were observed in patients with favorable or unfavorable prognosis, based on the mutational status of IGHV genes, with the lowest expression in the unfavorable prognosis group. Analysis of the expression of genes implicated in apoptosis defects of CLL showed an alteration in the balance of proapoptotic and antiapoptotic members of the Bcl-2 family in patients with CLL. Reconstitution experiments in CLL B cells, together with data obtained on B cells from p66Shc(-/-) mice, showed that p66Shc expression correlates with a bias in the Bcl-2 family toward proapoptotic members. The data identify p66Shc as a novel regulator of B-cell apoptosis which attenuates BCR-dependent survival signals and modulates Bcl-2 family expression. They moreover provide evidence that the p66Shc expression defect in CLL B cells may be causal to the imbalance toward the antiapoptotic Bcl-2 family members in these cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20061561     DOI: 10.1182/blood-2009-08-239244

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  p66Shc deficiency sets the scene for clinically aggressive chronic lymphocytic leukemia.

Authors:  Richard Rosenquist
Journal:  Haematologica       Date:  2019-10       Impact factor: 9.941

2.  p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β-arrestin at early endosomes.

Authors:  Laura Patrussi; Nagaja Capitani; Francesca Cattaneo; Noemi Manganaro; Alessandra Gamberucci; Federica Frezzato; Veronica Martini; Andrea Visentin; Pier Giuseppe Pelicci; Mario M D'Elios; Livio Trentin; Gianpietro Semenzato; Cosima T Baldari
Journal:  Oncogene       Date:  2018-01-12       Impact factor: 9.867

3.  Serine 392 phosphorylation modulates p53 mitochondrial translocation and transcription-independent apoptosis.

Authors:  Cédric Castrogiovanni; Béranger Waterschoot; Olivier De Backer; Patrick Dumont
Journal:  Cell Death Differ       Date:  2017-09-22       Impact factor: 15.828

4.  p66Shc Deficiency in Chronic Lymphocytic Leukemia Promotes Chemokine Receptor Expression Through the ROS-Dependent Inhibition of NF-κB.

Authors:  Vanessa Tatangelo; Gioia Boncompagni; Nagaja Capitani; Ludovica Lopresti; Noemi Manganaro; Federica Frezzato; Andrea Visentin; Livio Trentin; Cosima T Baldari; Laura Patrussi
Journal:  Front Oncol       Date:  2022-06-29       Impact factor: 5.738

5.  The pro-oxidant adaptor p66SHC promotes B cell mitophagy by disrupting mitochondrial integrity and recruiting LC3-II.

Authors:  Anna Onnis; Valentina Cianfanelli; Chiara Cassioli; Dijana Samardzic; Pier Giuseppe Pelicci; Francesco Cecconi; Cosima T Baldari
Journal:  Autophagy       Date:  2018-09-06       Impact factor: 16.016

6.  Diallyl trisulfide-induced prostate cancer cell death is associated with Akt/PKB dephosphorylation mediated by P-p66shc.

Authors:  Andzelika Borkowska; Alicja Sielicka-Dudzin; Anna Herman-Antosiewicz; Michal Wozniak; Donatella Fedeli; Giancarlo Falcioni; Jedrzej Antosiewicz
Journal:  Eur J Nutr       Date:  2011-10-22       Impact factor: 5.614

7.  Expression of the p66Shc protein adaptor is regulated by the activator of transcription STAT4 in normal and chronic lymphocytic leukemia B cells.

Authors:  Francesca Cattaneo; Laura Patrussi; Nagaja Capitani; Federica Frezzato; Mario Milco D'Elios; Livio Trentin; Gianpietro Semenzato; Cosima T Baldari
Journal:  Oncotarget       Date:  2016-08-30

8.  The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions.

Authors:  Samantha D Pauls; Sandrine T Lafarge; Ivan Landego; Tingting Zhang; Aaron J Marshall
Journal:  Front Immunol       Date:  2012-08-09       Impact factor: 7.561

9.  Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL.

Authors:  Dimitar G Efremov; Adrian Wiestner; Luca Laurenti
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-10-09       Impact factor: 2.576

10.  Negative regulation of chemokine receptor signaling and B-cell chemotaxis by p66Shc.

Authors:  L Patrussi; N Capitani; E Cannizzaro; F Finetti; O M Lucherini; P G Pelicci; C T Baldari
Journal:  Cell Death Dis       Date:  2014-02-20       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.